Sumitomo Pharma Co. Ltd. (DNPUF)

PNK: DNPUF · Real-Time Price · USD

5.80

1.70 (41.46%)

At close: May 01, 2025, 9:30 AM

Sumitomo Pharma Income Statement

Financials in JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Revenue	314.56B	555.54B	560.03B	515.95B	482.73B	459.27B	466.84B	411.64B	403.2B
Cost of Revenue	126.58B	178.92B	157.13B	137.77B	129.67B	113.55B	112.34B	100.08B	104.47B
Gross Profit	187.98B	376.63B	402.91B	378.18B	353.06B	345.71B	354.49B	311.57B	298.74B
Operating Income	-354.86B	-76.98B	60.23B	71.22B	83.24B	57.88B	88.17B	52.76B	36.93B
Interest Income	36.02B	32.22B	25.78B	9.21B	3.57B	7.37B	2.43B	746M	627M
Pretax Income	-323.11B	-47.92B	82.96B	77.85B	83.95B	65.05B	84.87B	47.22B	39.56B
Net Income	-314.97B	-74.51B	56.41B	56.22B	40.75B	48.63B	53.45B	31.32B	24.7B
Selling & General & Admin	429.54B	373.32B	249.08B	190.37B	154.35B	180.44B	183.65B	24.08B	26.96B
Research & Development	112.64B	131.86B	94.9B	132.68B	115.11B	102.36B	86.93B	80.82B	82.03B
Other Expenses	665M	n/a	n/a	n/a	n/a	n/a	n/a	-802M	-749M
Operating Expenses	542.84B	453.6B	342.67B	306.95B	269.82B	287.83B	266.32B	258.81B	261.8B
Interest Expense	4.28B	3.16B	3.05B	2.59B	2.86B	207M	5.74B	631M	919M
Selling & Marketing Expenses	n/a	59.86B	37.78B	37.36B	37.74B	37.98B	38.21B	24.08B	26.96B
Cost & Expenses	669.42B	632.52B	499.8B	444.73B	399.49B	401.38B	378.67B	358.88B	366.27B
Income Tax Expense	-8.19B	48.79B	42.36B	41.02B	48.03B	16.42B	31.42B	18.23B	14.86B
Shares Outstanding (Basic)	397.29M	397.29M	397.29M	397.29M	397.3M	397.3M	397.3M	397.3M	397.3M
Shares Outstanding (Diluted)	397.29M	397.29M	397.29M	397.29M	397.3M	397.3M	397.3M	397.3M	397.3M
EPS (Basic)	-792.79	-187.55	141.99	141.50	102.58	122.39	134.53	78.82	62.16
EPS (Diluted)	-792.79	-187.55	141.99	141.50	102.58	122.39	134.53	78.82	62.16
EBITDA	-317.37B	-3.5B	98.31B	76.97B	100.29B	75.25B	95.61B	56.18B	57.2B
EBIT	-318.84B	-44.76B	86.01B	80.44B	86.81B	65.25B	90.6B	52.76B	40.48B
Depreciation & Amortization	37.77B	41.26B	38.35B	22.67B	17.36B	13.98B	12.89B	12.71B	20.27B